Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivier Casez

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Multiple Sclerosis and Related Disorders|February 28, 2026
Risk of postpartum disease activity with subcutaneous versus intravenous Natalizumab in pregnant women with multiple sclerosisVito Ag Ricigliano, Doriana Landi, Marine Boudot de la Motte, et al.
Journal of Neurology|February 5, 2021
Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based studySergio Muñiz-Castrillo, Alberto Vogrig, Clémentine Montagnac, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 6, 2026
Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative studyMichaël Levraut, Mikael Cohen, Delphine Sterlin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 3, 2024
Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosisMelany Venet, Anne Lepine, Adil Maarouf, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 9, 2021
TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosisFrédéric Hilezian, Adil Maarouf, Clemence Boutiere, et al.
Annals of Clinical and Translational Neurology|August 8, 2025
Durable B-Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple SclerosisAlexandra Garcia, Stephane Rodriguez, Emilie Dugast, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 22, 2023
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple SclerosisAlexandra Garcia, Emilie Dugast, Sita Shah, et al.
Annals of Clinical and Translational Neurology|April 8, 2021
Comparison of Simoa<sup>TM</sup> and Ella<sup>TM</sup> to assess serum neurofilament-light chain in multiple sclerosisAudrey Gauthier, Sébastien Viel, Magali Perret, et al.
JAMA Network Open|June 23, 2023
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple SclerosisEdouard Januel, David Hajage, Pierre Labauge, et al.
Annals of Neurology|January 13, 2019
A proliferation-inducing ligand-mediated anti-inflammatory response of astrocytes in multiple sclerosisLaurie Baert, Mahdia Benkhoucha, Natalia Popa, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Multiple Sclerosis and Related Disorders|February 28, 2026
Risk of postpartum disease activity with subcutaneous versus intravenous Natalizumab in pregnant women with multiple sclerosisVito Ag Ricigliano, Doriana Landi, Marine Boudot de la Motte, et al.
Journal of Neurology|February 5, 2021
Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based studySergio Muñiz-Castrillo, Alberto Vogrig, Clémentine Montagnac, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 6, 2026
Kappa free light chain index or oligoclonal bands testing in clinical practice for multiple sclerosis diagnosis: An algorithm comparative studyMichaël Levraut, Mikael Cohen, Delphine Sterlin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 3, 2024
Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosisMelany Venet, Anne Lepine, Adil Maarouf, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 9, 2021
TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosisFrédéric Hilezian, Adil Maarouf, Clemence Boutiere, et al.
Annals of Clinical and Translational Neurology|August 8, 2025
Durable B-Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple SclerosisAlexandra Garcia, Stephane Rodriguez, Emilie Dugast, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 22, 2023
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple SclerosisAlexandra Garcia, Emilie Dugast, Sita Shah, et al.
Annals of Clinical and Translational Neurology|April 8, 2021
Comparison of Simoa<sup>TM</sup> and Ella<sup>TM</sup> to assess serum neurofilament-light chain in multiple sclerosisAudrey Gauthier, Sébastien Viel, Magali Perret, et al.
JAMA Network Open|June 23, 2023
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple SclerosisEdouard Januel, David Hajage, Pierre Labauge, et al.
Annals of Neurology|January 13, 2019
A proliferation-inducing ligand-mediated anti-inflammatory response of astrocytes in multiple sclerosisLaurie Baert, Mahdia Benkhoucha, Natalia Popa, et al.
Pageof 6